(NASDAQ: TTRX) Turn Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.98%.
Turn Therapeutics's earnings in 2026 is -$8,445,820.On average, 4 Wall Street analysts forecast TTRX's earnings for 2026 to be -$7,899,788, with the lowest TTRX earnings forecast at -$11,676,912, and the highest TTRX earnings forecast at -$3,753,293. On average, 4 Wall Street analysts forecast TTRX's earnings for 2027 to be -$11,393,925, with the lowest TTRX earnings forecast at -$11,384,989, and the highest TTRX earnings forecast at -$11,259,879.
In 2028, TTRX is forecast to generate -$13,976,548 in earnings, with the lowest earnings forecast at -$13,428,448 and the highest earnings forecast at -$14,387,623.